Sunday, 22 November 2026 SEC EDGAR filings, as they land
ALFAFINDER USA News Straight from the SEC filing
SEC Filings
Clinical Trial Data

Pyxis Oncology Shares Skyrocket 38% in 1 Day Since Other

Pyxis Oncology Reports 39% Confirmed ORR in Phase 1 Study for Head and Neck Cancer

+38.21% in 1 day $1.41 when we broke this story → $1.95 at 10:14 AM ET, 20 Nov 2026

Pyxis Oncology released updated Phase 1 monotherapy data for its lead candidate, micvotabart pelidotin (MICVO), targeting recurrent or metastatic head and neck squamous cell carcinoma. The findings demonstrate significant clinical activity and a manageable safety profile, supporting the transition to a global Phase 3 clinical trial expected to begin in mid-2027.

Glasses, book, education, eyeglasses. Stock photo illustrating Pyxis Oncology's other story.
Pyxis Oncology, Inc. · Healthcare · Photo: DariuszSankowski / Pixabay

Key highlights

  • Confirmed objective response rate reached 39% among 33 efficacy-evaluable patients
  • Median progression-free survival recorded at 6.7 months as of October 2026
  • Overall survival probability at 12 months estimated at 81% for the study cohort
  • Median duration of response stood at 9.2 months, highlighting durable clinical benefit
  • Safety data showed no new cases of Grade 3 peripheral neuropathy under new dose-capping protocols

Clinical Trial Advancements

Pyxis Oncology presented updated results from its global Phase 1 monotherapy study of micvotabart pelidotin (MICVO) at the EORTC-NCI-AACR Symposium. The data, updated as of October 14, 2026, focused on patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma. Results showed deep and durable responses, including a 94% disease control rate. Notably, a novel analysis revealed that MICVO increased median progression-free survival by 50% compared to the most recent prior therapies received by the participants. The company also highlighted improved safety outcomes through effective dose-capping strategies designed for patients above specific weight thresholds.

Strategic Significance

  • Clinical activity remained consistent across diverse subgroups, including HPV-positive and HPV-unrelated patients
  • New safety protocols resulted in 83% of Grade 3 peripheral neuropathy cases resolving to Grade 1 or better
  • The October update provides a definitive data profile to support the upcoming Phase 3 Headliner trial
  • Company plans to initiate regulatory meetings in the near term to finalize late-stage development paths
  • More mature overall survival data is anticipated in the first half of 2027 to further validate the drug profile

Business and Industry Context

Based in Boston, Pyxis Oncology is a clinical-stage biopharmaceutical company specialized in developing next-generation therapeutics, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Their lead ADC candidate, MICVO, leverages proprietary linker-payload technology to target difficult-to-treat cancers. The head and neck cancer market represents a significant unmet medical need for patients who fail platinum-based chemotherapy and immunotherapy. By demonstrating durable responses in these later-line settings, Pyxis is positioning itself within a high-growth oncology sector currently focused on ADC innovation to replace traditional chemotherapy regimens.

Financial Performance

  • Pyxis Oncology currently carries a market capitalization of approximately $168.6 million on the NASDAQ Global Select Market
  • The stock is trading with a 14-day Relative Strength Index of 30.2, indicating it is nearing oversold territory
  • Annual revenue for the trailing twelve months stands at $13.858 million, reflecting the company's clinical-stage focus
  • The company experienced a 53.3% share price decline over the last quarter amid broader biotech sector volatility
Pyxis Oncology, Inc. share price · last month
Line chart of Pyxis Oncology, Inc.'s share price over the last month, from $1.76 on 21 Oct → $1.81 on 20 Nov; our story on 19 Nov at $1.41.

Up 28.4% since our story on 19 Nov: $1.41 when we broke it → $1.81 at the close on 20 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
21 Oct$1.76
22 Oct$1.71
23 Oct$1.68
26 Oct$1.69
27 Oct$1.84
28 Oct$1.98
29 Oct$1.89
30 Oct$1.81
2 Nov$1.69
3 Nov$1.64
4 Nov$1.66
5 Nov$1.61
6 Nov$1.66
9 Nov$1.70
10 Nov$1.63
11 Nov$1.64
12 Nov$1.58
13 Nov$1.58
16 Nov$1.41
17 Nov$1.44
18 Nov$1.41
19 Nov$1.68
20 Nov$1.81

Management commentary

“The data from October show improvements across multiple key clinical activity endpoints with a novel analysis showing that MICVO increased mPFS by 50% versus the most recent prior therapy patients had received before MICVO. We are also very happy to report that our clinical strategy for managing safety has had the intended impact.”

Tom Civik, Chief Executive Officer and Chairman of Pyxis Oncology
Pyxis Oncology, Inc. · financial snapshot
Share price$1.41
Market cap$169M
Revenue (annual)$14M
1-month price change-19.89%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Pyxis Oncology, Inc. announcing updated Phase 1 clinical data for MICVO and plans for a Phase 3 trial.

Read the filing ↗

Track Pyxis Oncology, Inc. live

Get the next Pyxis Oncology, Inc. SEC filing seconds after it lands.

Get Alerts

Get ALFAFINDER USA alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.